| Company Name: |
Fuan Bio |
| Tel: |
15002819872 |
| Email: |
2845971812@qq.com |
|
| | Veldoreotide Basic information |
| Product Name: | Veldoreotide | | Synonyms: | ABFNTRQPWNXUHA-UHFFFAOYSA-N;Glycinamide, N-(4-amino-1-oxobutyl)-L-phenylalanyl-L-tryptophyl-D-tryptophyl-L-lysyl-L-threonyl-L-phenylalanyl-N2-(3-carboxypropyl)-, (7→1)-lactam;Veldoreotide;DG-3173 | | CAS: | 252845-37-7 | | MF: | C60H74N12O10 | | MW: | 1123.30396 | | EINECS: | | | Product Categories: | | | Mol File: | 252845-37-7.mol |  |
| | Veldoreotide Chemical Properties |
| Boiling point | 1527.8±65.0 °C(Predicted) | | density | 1.226±0.06 g/cm3(Predicted) | | pka | 13.23±0.70(Predicted) |
| | Veldoreotide Usage And Synthesis |
| Uses | Veldoreotide (DG3173) a somatostatin analogue, binds to and activate the somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide inhibits growth hormone (GH) secretion in adenomas compared with Octreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent[1] | | IC 50 | SSTR2: 37.6 nM (EC50); SSTR3: 31.3 nM (EC50); SSTR4: 10.5 nM (EC50) | | References | [1] Dasgupta P, et al. Pharmacological Characterization of Veldoreotide as a Somatostatin Receptor 4 Agonist. Life (Basel). 2021 Oct 12;11(10):1075. DOI:10.3390/life11101075
[2] Plckinger U, et al. DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours. Eur J Endocrinol. 2012 Feb;166(2):223-34. DOI:10.1530/EJE-11-0737 |
| | Veldoreotide Preparation Products And Raw materials |
|